{"id":476,"date":"2026-08-28T06:56:06","date_gmt":"2026-08-28T06:56:06","guid":{"rendered":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/"},"modified":"2026-09-01T09:40:18","modified_gmt":"2026-09-01T09:40:18","slug":"aod-9604-options-essai-resultat-de-perte-de-poids-nul","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/aod-9604-options-trial-null-weight-loss-result\/","title":{"rendered":"\u00c9tude AOD-9604 OPTIONS\u00a0: r\u00e9sultat principal, r\u00e9sultat nul et limites des preuves"},"content":{"rendered":"
AOD-9604 a progress\u00e9 au-del\u00e0 du travail sur les animaux pour devenir un programme de d\u00e9veloppement de l'ob\u00e9sit\u00e9. La revue 2024 de FDA indique que la vaste \u00e9tude OPTIONS n\u2019a pas montr\u00e9 de perte de poids statistiquement significative par rapport au placebo et que le d\u00e9veloppement de l\u2019ob\u00e9sit\u00e9 a pris fin.<\/p>
Ce que montre le dossier<\/h2>
Le briefing FDA enregistre les participants 536 inscrits et les participants randomis\u00e9s 502\u00a0; une figure de sponsor reproduite est \u00e9tiquet\u00e9e \u00ab\u00a0Toutes les donn\u00e9es N=503\u00a0\u00bb.<\/li>
La perte de poids par rapport au placebo aux semaines 12 et 24 \u00e9tait trop faible pour atteindre une signification statistique.<\/li>
FDA n'a pas pu localiser une publication compl\u00e8te dans une revue m\u00e9dicale contenant les m\u00e9thodes d'\u00e9tude et les d\u00e9tails pr\u00e9liminaires de l'efficacit\u00e9.<\/li><\/ul><\/div><\/div>Illustration \u00e9ditoriale originale du contexte de recherche. Il ne s'agit pas d'une figure d'\u00e9tude, d'une image de patient, d'une photographie du produit fourni ou d'une repr\u00e9sentation du mat\u00e9riel d'essai.<\/figcaption><\/figure>
Dossier d'\u00e9tudes<\/h2>
Le briefing de FDA cite la conclusion du promoteur selon laquelle la population \u00e9tudi\u00e9e dans son ensemble n\u2019a pas r\u00e9pondu de mani\u00e8re coh\u00e9rente et que les r\u00e9sultats n\u2019ont pas soutenu le d\u00e9veloppement de l\u2019ob\u00e9sit\u00e9 commerciale. Ce bilan n\u00e9gatif a plus de poids que les premiers signaux isol\u00e9s.<\/p>
Programme<\/strong>\u00c9tude de d\u00e9veloppement de l'ob\u00e9sit\u00e9 OPTIONS phase IIb<\/span><\/div>
Inscrit<\/strong>Participants au 536<\/span><\/div>
Randomis\u00e9<\/strong>Participants 502 au r\u00e9cit FDA<\/span><\/div>
Etiquette du personnage du sponsor<\/strong>Toutes les donn\u00e9es, N=503\u00a0; reproduit dans le briefing FDA<\/span><\/div>
Interpr\u00e9tation principale<\/strong>Aucune diff\u00e9rence de perte de poids statistiquement significative par rapport au placebo<\/span><\/div>
R\u00e9sultat de d\u00e9veloppement<\/strong>Fin du programme d'ob\u00e9sit\u00e9<\/span><\/div><\/div><\/div>
R\u00e9sultats en contexte<\/h2>
Le d\u00e9ficit de publication est important. Sans un rapport complet \u00e9valu\u00e9 par des pairs, les lecteurs ne peuvent pas inspecter de mani\u00e8re ind\u00e9pendante toutes les analyses pr\u00e9d\u00e9finies, le traitement des donn\u00e9es manquantes et les d\u00e9cisions des sous-groupes.<\/p>
AOD-9604 doit donc \u00eatre d\u00e9crit comme un fragment exp\u00e9rimental de GH avec un crit\u00e8re de d\u00e9veloppement de l\u2019ob\u00e9sit\u00e9 qui a \u00e9chou\u00e9, et non comme un \u00ab peptide br\u00fble-graisse \u00bb cliniquement prouv\u00e9.<\/p>
Ce \u00e0 quoi cette \u00e9tude ne peut pas r\u00e9pondre<\/h2>
Les d\u00e9tails les plus importants des essais \u00e0 grande \u00e9chelle se trouvent dans les dossiers r\u00e9glementaires et de l'entreprise plut\u00f4t que dans un rapport d'essai complet \u00e9valu\u00e9 par des pairs.<\/p>
L\u2019\u00e9chec du d\u00e9veloppement de l\u2019ob\u00e9sit\u00e9 ne r\u00e9pond pas \u00e0 toutes les questions de laboratoire, mais il contredit directement les all\u00e9gations confiantes de perte de poids chez l\u2019homme.<\/p>","protected":false},"excerpt":{"rendered":"
AOD-9604 a progress\u00e9 au-del\u00e0 du travail sur les animaux pour devenir un programme de d\u00e9veloppement de l'ob\u00e9sit\u00e9. La revue 2024 de FDA indique que la vaste \u00e9tude OPTIONS n\u2019a pas montr\u00e9 de perte de poids statistiquement significative par rapport au placebo et que le d\u00e9veloppement de l\u2019ob\u00e9sit\u00e9 a pris fin.<\/p>","protected":false},"author":1,"featured_media":641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"314","pim_article_type":"Published study case","pim_evidence_level":"FDA-reviewed development record; pivotal result not published as a full journal trial","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA December 2024 AOD-9604 briefing document\",\"url\":\"https:\/\/www.fda.gov\/media\/183584\/download\",\"note\":\"FDA review of effectiveness, safety and the OPTIONS result.\"},{\"title\":\"AOD-9604 development review\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15134286\/\",\"note\":\"Contemporaneous development summary; PMID 15134286.\"},{\"title\":\"FDA December 2024 PCAC meeting record\",\"url\":\"https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-meeting-time-and-public-participation-information-december-4-2024-meeting-pharmacy\",\"note\":\"Regulatory meeting context.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\n
AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits - NHD<\/title>\n<meta name=\"description\" content=\"AOD-9604 progressed beyond animal work into an obesity-development program. FDA\u2019s 2024 review records that the large OPTIONS study did not show statistical\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/aod-9604-options-essai-resultat-de-perte-de-poids-nul\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits\" \/>\n<meta property=\"og:description\" content=\"AOD-9604 progressed beyond animal work into an obesity-development program. FDA\u2019s 2024 review records that the large OPTIONS study did not show statistical\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/aod-9604-options-essai-resultat-de-perte-de-poids-nul\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T09:40:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits\",\"datePublished\":\"2026-08-28T06:56:06+00:00\",\"dateModified\":\"2026-09-01T09:40:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/\",\"name\":\"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:06+00:00\",\"dateModified\":\"2026-09-01T09:40:18+00:00\",\"description\":\"AOD-9604 progressed beyond animal work into an obesity-development program. FDA\u2019s 2024 review records that the large OPTIONS study did not show statistical\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/aod-9604-options-trial-null-weight-loss-result\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u00c9tude AOD-9604 OPTIONS\u00a0: r\u00e9sultat principal, r\u00e9sultat nul et limites des preuves - NHD","description":"AOD-9604 a progress\u00e9 au-del\u00e0 du travail sur les animaux pour devenir un programme de d\u00e9veloppement de l'ob\u00e9sit\u00e9. L'examen 2024 de FDA indique que la grande \u00e9tude OPTIONS n'a pas montr\u00e9 de statistiques\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/aod-9604-options-essai-resultat-de-perte-de-poids-nul\/","og_locale":"fr_FR","og_type":"article","og_title":"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits","og_description":"AOD-9604 progressed beyond animal work into an obesity-development program. FDA\u2019s 2024 review records that the large OPTIONS study did not show statistical\u2026","og_url":"https:\/\/nhdbio.com\/fr\/aod-9604-options-essai-resultat-de-perte-de-poids-nul\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:06+00:00","article_modified_time":"2026-09-01T09:40:18+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits","datePublished":"2026-08-28T06:56:06+00:00","dateModified":"2026-09-01T09:40:18+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/","url":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/","name":"\u00c9tude AOD-9604 OPTIONS\u00a0: r\u00e9sultat principal, r\u00e9sultat nul et limites des preuves - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp","datePublished":"2026-08-28T06:56:06+00:00","dateModified":"2026-09-01T09:40:18+00:00","description":"AOD-9604 a progress\u00e9 au-del\u00e0 du travail sur les animaux pour devenir un programme de d\u00e9veloppement de l'ob\u00e9sit\u00e9. L'examen 2024 de FDA indique que la grande \u00e9tude OPTIONS n'a pas montr\u00e9 de statistiques\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/aod-9604-options-trial-null-weight-loss-result-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/aod-9604-options-trial-null-weight-loss-result\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=476"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/476\/revisions"}],"predecessor-version":[{"id":713,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/476\/revisions\/713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/641"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Un](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/gh-secretagogue-research-20260828.png\")